Skip to main content

Step-Up Glofitamab Dosing Induces High Response Rates in Relapsed or Refractory Non-Hodgkin Lymphoma

JHOP - February 2021 Vol 11, No 1 - ASH Highlights, Clinical Trials, Lymphoma
Download pdf

A new step-up dosing schedule with glofitamab, an investigational T-cell engaging bispecific antibody, has demonstrated strong clinical activity, with high complete response rates in patients with hard-to-treat relapsed or refractory non-Hodgkin lymphoma (NHL), according to data presented at the ASH 2020 annual meeting.

The results of the first-in-human clinical trial of glofitamab showed more than 50% complete response rates. The study included pretreatment with obinutuzumab, which was intended to reduce cytokine release syndrome (CRS) and to enable an increasing dosing schedule. The majority of patients were still receiving treatment with glofitamab at the data cutoff.

“Step-up dosing of glofitamab combined with obinutuzumab pretreatment is a useful CRS-mitigation strategy. The new dosing strategy allowed administration of a high glofitamab target dose of 30 mg, which is higher than the maximum tolerated dose when using a fixed-dose regimen, and with a lower risk of CRS grade 2 or higher,” said lead study investigator Martin Hutchings, MD, PhD, of Rigshospitalet, Copenhagen, Denmark.

For this clinical trial, patients received 1000 mg obinutuzumab 7 days before the first administration of glofitamab. Glofitamab was given intravenously every 3 weeks for up to 12 cycles, with step-up doses starting at 2.5 mg, then 10 mg, and then 16 mg or 30 mg. Inclusion criteria included a diagnosis of relapsed or refractory CD20-positive B-cell NHL, in adults who received at least 1 previous line of therapy, measurable disease, adequate organ function, and good performance status (grade 0 or 1).

A total of 52 patients were enrolled in the study (median age, 68 years). The patients were heavily pretreated, with a median of 3 previous lines of therapy, and the majority of patients had disease refractory to the most recent line of therapy and to an anti–CD20-containing therapy regimen.

More than 50% of the patients had aggressive lymphomas, and all patients with indolent lymphomas had follicular lymphoma, grade I to IIIA.

“Compared with fixed-dose cohorts, the high response rates in follicular lymphoma are maintained, while the complete response rates in aggressive lymphomas appear higher in the step-up cohorts,” said Dr Hutchings, who noted that the vast majority of both aggressive and indolent lymphomas had clear tumor regressions.

“Complete response rates in both groups were higher than 50%,” Dr Hutchings added.

At the time of the data cutoff, the majority of patients were in remission and were still receiving treatment. In patients with aggressive lymphoma, 13 of the 15 complete remissions are ongoing, whereas in patients with follicular lymphoma, all 13 complete remissions are ongoing.

Almost all patients had ≥1 adverse events. Serious treatment-related adverse events were observed in approximately 50% of the patients, and no fatal adverse events were reported, said Dr Hutchings. Only 2 adverse events led to treatment discontinuation.

Cytokine Release Syndrome

Of note, the CRS-mitigation strategy was successful.

“Although overall rates of CRS were similar between the fixed-dosing and step-up dosing cohorts, step-up dosing reduced the frequency of grade 2 or higher CRS,” said Dr Hutchings. Furthermore, 36% of patients who received fixed dosing of ≥10 mg had more serious CRS compared with 31% of patients in the step-up dosing cohorts.

All patients who received the 25-mg fixed dose had CRS after the first administration, and the majority of cases were grade ≥2. By contrast, only 25% of patients in the step-up dosing cohort had CRS after their first treatment with the target dose of 30 mg glofitamab.

Of the 52 patients enrolled on study, 64% had CRS, but only 2 patients had CRS higher than grade 2. CRS events were also confined to cycles 1 and 2, said Dr Hutchings. The median time to CRS from the first glofitamab dose was 14 hours, with a median duration of 29 hours.

Tocilizumab was used to manage CRS in 8 patients. In all, 3 patients were admitted to an intensive care unit; 8 patients received low-flow oxygen; 3 patients received single vasopressors; and 1 patient required mechanical ventilation.

Overall, the safety profile of glofitamab after the step-up dosing was manageable, Dr Hutchings concluded.

Related Items
Pyrexia Management in Patients with Melanoma Treated with Dabrafenib/Trametinib Combination Therapy
August 2022 Clinical Trials to Clinical Practice published on August 23, 2022 in Clinical Trials, Melanoma
Yescarta First CAR T-Cell Therapy FDA Approved for Large B-Cell Lymphoma
JHOP - June 2022 Vol 12, No 3 published on June 16, 2022 in FDA Oncology Update, CAR T-Cell Therapy, Lymphoma
Kymriah Received Accelerated FDA Approval for Relapsed or Refractory Follicular Lymphoma
JHOP - June 2022 Vol 12, No 3 published on June 16, 2022 in FDA Oncology Update, Lymphoma, CAR T-Cell Therapy
Evaluation of Clinical Pharmacy Services for Phase 1 Clinical Trials
JHOP - June 2022 Vol 12, No 3 published on June 16, 2022 in Original Article, Clinical Trials, Oncology Pharmacy Protocols
Second-Line Axicabtagene Ciloleucel Therapy Improves Outcomes in Patients with Large B-Cell Lymphoma: ZUMA-7
Robert J. Ignoffo, PharmD, FASHP, FCSHP, FHOPA
JHOP - April 2022 Vol 12, No 2 published on May 3, 2022 in From the Literature, Lymphoma, CAR T-Cell Therapy
Hepatitis B Virus Infection Monitoring in Patients with Lymphoma Receiving Anti-CD20 Monoclonal Antibodies
Christopher Sinoimeri, PharmD, Bryan Do, PharmD, BCOP, Sheree Chen, PharmD, BCOP
JHOP - April 2022 Vol 12, No 2 published on May 3, 2022 in Original Article, Lymphoma, Immunotherapy, Infections
A Pooled Safety Analysis of Loncastuximab Tesirine in Relapsed or Refractory DLBCL in the LOTIS Clinical Trial Program: Incidence, Onset, and Management of Myelosuppression
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts, Lymphoma
Mosunetuzumab, a Bispecific Antibody, Induces Deep Remissions in Relapsed or Refractory Follicular Lymphoma
JHOP - February 2022 Vol 12, No 1 published on March 1, 2022 in ASH Highlights
Time-Limited Venetoclax Combinations Superior to Chemoimmunotherapy in Fit Patients with CLL
JHOP - February 2022 Vol 12, No 1 published on March 1, 2022 in ASH Highlights
Isatuximab plus RVd Regimen Achieves Highest Rates of No MRD in Patients with Multiple Myeloma
JHOP - February 2022 Vol 12, No 1 published on March 1, 2022 in ASH Highlights